The global hereditary angioedema (HAE) treatment market is witnessing rapid growth, fueled by rising awareness, innovative drug developments, and expanding patient populations worldwide. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of severe swelling, often affecting the limbs, face, intestinal tract, and airway. Timely diagnosis and advanced treatment options are crucial to managing this life-threatening condition effectively.
According to Fortune Business Insights, the hereditary angioedema treatment market was valued at USD 5.59 billion in 2024. The market is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during 2025-2032. In 2024, North America dominated the hereditary angioedema treatment market with a market share of 93.05%.
Top Companies in the Market
- CSL Behring
- Shire plc.
- Pharming Group NV
- BIOCRYST PHARMACEUTICALS, INC.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum
- Other prominent players
Market Drivers & Restraints
Market Drivers
- Increasing Disease Awareness: Enhanced awareness campaigns and improved diagnostic techniques have led to earlier identification and intervention, driving demand for effective treatments.
- Technological Advancements: Continuous R&D activities have led to the development of targeted therapies such as C1 esterase inhibitors and monoclonal antibodies that offer greater efficacy and safety profiles.
- Supportive Regulatory Approvals: Regulatory bodies like the FDA and EMA have been proactive in fast-tracking approvals for promising new therapies, accelerating their market availability.
- Growing Patient Support Programs: Pharmaceutical companies are investing in patient education and support programs, improving treatment adherence and patient outcomes.
Market Restraints